Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Doxorubicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Doxorubicin overview
Legubicin (QHL-108, doxorubicin) is under development for the treatment of advanced malignant solid tumors, advanced or recurrent or metastatic soft tissue sarcoma, alveolar soft tissue sarcoma, clear cell sarcoma, gastrointestinal stromal tumor, vascular endothelial sarcoma, breast cancer, gastric cancer, ovarian cancer, lung adenocarcinoma and hemangioendothelial sarcoma. It is administered through intravenous drip. The drug candidate acts by targeting DNA topoisomerase II. It is being developed based on tumor micro environment activated (TMEA) platform.
Shanghai Affinity Biopharmaceutical overview
Shanghai Affinity Biopharmaceutical (Affinity Biopharma) is a clinical-stage biopharmaceutical company. The company develops tumor microenvironment-activated (TMEA) intelligent platforms for small-molecule drugs and biologics. It offers an oral antibacterial bio gel product, Gelsooth, for oral protection and antibacterial care. Affinity Biopharma’s TMEA platform technology includes TMEA small molecule drug conjugates, TMEA cytokine, TMEA antibody, TMEA antibody-drug conjugates, TMEA fusion cytokine, and TMEA immune cell engager. The company is developing a broad range of products pipeline in the areas of precision-guided chemotherapy, precision-guided target therapy, and biologics conjugates for cancer treatments. Affinity Biopharma is headquartered in Shanghai, China.
For a complete picture of Doxorubicin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
